Why Microbix Biosystems Inc. stock is skyrocketing today --- wealthawesome.com/why-microb…

Why Microbix Biosystems Inc. stock is gaining today --- wealthawesome.com/why-microb…

Why Microbix Biosystems Inc. stock is rising today --- wealthawesome.com/why-microb…

Big thank you to the team at Bloom Burton for hosting another excellent event full of leaders, investors, and healthcare innovators. 📷 @Microbix pictured: CEO Ken d'Entremont with a coffee, CFO Jim Currie and COO Ken Hughes share a smile, COO Ken Hughes presents. #BBHIC2026 $MBX

A critical supplier to the global medical diagnostics industry; @Microbix CEO Cameron Groome presented and attended 1x1 meetings across Canada this week. 🔵🔴 Discussion highlights: - Q1 FY2026 revenue up 13% sequentially - $9.1M cash position - Targeting return to quarterly profitability by late FY2026 With ~100 global diagnostic programs, expanding QAPs™ growth, and the fully funded Kinlytic royalty opportunity, #Microbix combines durable core cash flows with asymmetric upside. $MBX $MBXBF

Cervical cancer is largely preventable - yet ~350,000 women still die every year. The problem isn’t awareness. It’s outdated systems and uneven access. Screening is undergoing a global shift: ➡️ Pap cytology → primary HPV testing → self-sampling Driven by higher sensitivity, >99% NPV, and risk-based guidelines aligned with WHO elimination targets. But better tests only work if results are reliable everywhere. That’s why quality systems and standardized controls - like those developed by @Microbix - matter, ensuring HPV testing performs consistently across labs, countries, and collection methods. From evidence to policy to implementation, this article breaks down where cervical cancer screening is headed, and what must happen next. 👇 🔗 Read the full article: oncodaily.com/insight/cervic… @Microbix @WHO @AmericanCancer @smarkosyann #CervicalCancer #HPV #CancerPrevention #WomensHealth #GlobalHealth #PublicHealth #Oncology #Screening #OncoDaily #MedTwitter #WomensHealth

This holiday season, many families are facing food insecurity at a time when no one should have to. Through our Give Back Webinar Series, $52,000 has so far been raised to support food banks around the world, helping provide meals and relief to communities that need it most. We’re grateful to the companies that participated in the series to support this cause: @1911goldcorp · @amtungsten · @ATEX_Resources · @BorealisMining · @bnkrhillmining · @OreContango · @CRECORP · @SilverVarden · @GoldQuest_GQC · @iFabricCorp · @IntegraResource · @LeviathanMetals · @Li_FTPower · $MFG.V · @Microbix · @NewcoreGold · @panglobalspain · @ParexResources · @PinnacleAuAg · @revivalgoldinc · $RBY.V · @ScottieCorp · @SierraMadreSM · @TantalusCorp · @usgoldcorp. · @VZZ_mining Thank you for helping make a difference this holiday season!

🚨 Qilin Ransomware Claims 3 Victims 🇺🇸 Lorber, Greenfield & Polito, LLP 🇨🇦 Microbix Biosystems 🇺🇸 Productive Tool Products

🚨 🇨🇦 Alleged Ransomware Claim Industry: Healthcare Group: qilin Victim: Microbix Biosystems Discovered: 2025-10-28 15:47 UTC

“This is a rare convergence of safe-haven demand and growth-driven equity momentum. #Preciousmetals keep breaking records while global indices hover near highs, reshaping how capital is being deployed.” — @RyanIverson_, CEM Partner and Portfolio Manager. This weekend, the Muskoka Capital Event takes place against this extraordinary backdrop, where about 50 of North America’s most promising growth-stage companies will connect directly with top-tier investors. At the event, the Investor Breakout Exchange Forum will once again spotlight the Top Picks and Outstanding Performers for the final time this year. Four Top Picks from the 2024 Muskoka Capital Event delivered a combined 102% gain YoY. See the full lineup of companies that could be added to the list of Top Picks and Outstanding Performers: bit.ly/48AP0D6 __ @alliedcritical @AngkorResources @AtlasSalt @brixtonmetals @e3lithium @eminent_gold @FirstPhosphate @FrontierLithium @GoldTerra @copper_gunnison @HalconesPM @hayasametals @HemisphereHME @highland_copper @HomelandUranium @honeybadgertuf @HydreightIV @IdexMetals @LibertyStreamIP @LibraLithium @lightaihealth @Lithium_Royalty @LucaMining @Microbix @MidnightSunMine @MustGrowBio @neo_battery @neoterrex @OcumeticsTech @RelevantGold @RuaGold @Silver47co @skeenagoldsilv @Skyharbour_SYH @SrananGold @StandardUranium @Trident_RSC @ValOreMetals @voyageurpharma @WhiteGoldCorp @YukonMetals @ZeusMiningCorp @CapitalEvent @MarketOneMedia @FarhanLalani @NCurrie #Metals #Mining #Tech #Biotech #AgriTech #Investing #Investment

Microbix Presenting at Muskoka Capital Event - Read the full press release here: microbix.com/resources/news-…

Big Pharma's 'Clot Busting' Drug, UROKINASE, Is A Billion Dollar Industry Steeped In Unethical Deception... Historically, Derived From Human Urine Collected From 1000s Of Gallons From Public Portable Toilets. Today, Most Urokinase Is Made From The Kidneys Of Stillborn Babies. Enzymes of America collected urine from the portable toilets of its subsidiary, Porta-John. This allowed the company to obtain the human urine needed to extract valuable enzymes & proteins for sale to pharmaceutical companies. Enzymes of America was originally formed to make use of the vast amount of waste collected by the portable toilet business. Business grew exponentially & it became labor intensive to keep up with demand. Blood Clot Eliminating (Clot Busting) medications like Urokinase are used for pulmonary embolisms & deep vein thrombosis, heart attacks & strokes. These conditions have skyrocketed in recent years, thus the demand for Urokinase is at an all time high. The high volume of Urokinase production & extraction today is from human kidneys, specifically neonatal kidneys from (stillborn) unborn babies, where the Urokinase enzyme is extracted straight from the kidneys after organ harvesting. Microbix Biologics Brand Kinlytic states, "Kidney donations are obtained exclusively in the United States from neonates (birth to 28 days) for whom death has not been attributed to infectious causes & that have exhibited no evidence of an infectious disease based in part, on an examination of the maternal & neonatal donor medical records." Some of today's Urokinase also comes from recombinant DNA using CHO Chinese Hamster Ovary as the growth factor. For recombinant Urokinase, the human gene that codes for Urokinase is inserted into CHO cells. These cells are then grown in large bioreactors to express & produce the Urokinase enzyme protein. 👇Urokinase From Unborn Human Babies👇 accessdata.fda.gov/drugsatfd… 👇Unethical Trafficked Kidneys For Urokinase👇 jvir.org/article/S1051-0443(… 👇Chinese Hamster Ovary For Urokinase Use👇 pubmed.ncbi.nlm.nih.gov/9684… Speaker: @realjasonshurka Jason Shurka Podcast: @Lis_unlimited Elisabeth Carson

Ontario innovation at its finest! 🥼🔬 I had the opportunity to visit @Microbix in Mississauga and see how they’re developing advanced diagnostic technologies that strengthen health systems worldwide. Companies like Microbix showcase the excellence of Ontario and Canadian talent — driving progress here at home while making an impact on the global stage. 🇨🇦🌎

🎗️Cervical cancer is preventable, yet thousands of lives are lost each year. Microbix CEO Cameron Groome shares how reliable diagnostics & HPV quality controls can advance screening programs worldwide. 👉 Read more: microbix.com/resources/artic… #LeadershipMatters #Microbix #POCT

MICROBIX BIOSYSTEMS INC - PRODUCTS EXEMPT FROM U.S. TARIFFS UNDER USMCA

🔴How To Navigate Through Tariffs 🔴 President Trump's tariffs (and Canada's counter-tariffs) have made the headlines almost daily over the last few months. It seems like there's always a new twist. Tariffs are on, then off, then on for specific product categories, then off, etc. The result is a lot of uncertainty. And financial markets hate uncertainty. As I write this, the S&P500 and Nasdaq Composite indices are down 4.3% and 9.5% year-to-date, respectively. In Canada, the S&P/TSX Composite index is off 5.8% from its January peak. The Canadian dollar is also under pressure, reaching a multi-year low of $0.68 against the USD last month. During such a period of volatility, I'm sure the question on everyone's mind is: What should I do? Is this a minor pullback or the start of a prolonged bear market? It's hard to believe that Trump intends to tank the stock market and make everyone poorer on paper, on top of an expected resurgence in inflation due to tariffs. That said, I'm puzzled as to what his intentions really are. As in poker, we'll have to make educated guesses with imperfect information here. Here's my take on the situation and how I'm thinking about the optimal way to position a portfolio currently. Please remember that this is not investment advice, as your situation may differ from mine. My goal is to help you think about your portfolio and how to adjust it if necessary. Let's start! 🚫 What I'm Avoiding or Reducing 🚫 ⚠️ Companies selling products to the US. At the risk of stating the obvious, companies that ship products across the border to the US should be affected by tariffs unless their product is highly differentiated with a moat. One example where I think risk is mitigated is Microbix Biosystems $MBX.TO, which sells regulated medical devices to US customers. There aren't many readily available alternatives for some of their SKUs, and the switching costs would be high for customers. On the other hand, companies selling commodities or undifferentiated products with many US-made alternatives appear riskier here. ⚠️ Companies that are cyclical or sensitive to the economy. Depending on how far Trump takes this trade war, there's a risk it might tip the US and/or other countries into recessions. Anything that's tied to the health of the economy could suffer. Examples could be companies selling highly discretionary consumer goods or AdTech companies that depend on advertising budgets from large corporations. ⚠️ Companies that need to raise capital. As you can see below, the market is in extreme fear territory. If the market environment deteriorates further, the financing activity will likely dry up again, like we've seen in microcaps during 2022-2023. I would favour companies with strong balance sheets and no refinancing risk at the moment. 👍 What I'm Keeping or Adding To 👍 ✅ US companies selling in the US. There are a few instances of Canadian-listed companies that are domiciled in the US and predominantly sell into the US market. These companies could benefit from protectionist measures and not be impacted by them. If a baby gets thrown out with the bath water, it could present a good entry point. One example I'm watching is California Nanotechnologies $CNO.V, a California-based company that derives most of its revenues from US customers despite its Canadian stock listing. ✅ Canadian companies selling in Canada. Canadian companies selling domestically should do well if protectionist measures are enabled on both sides of the border. The main risk would obviously be a recession in Canada. For this reason, I favour domestic industries that should be recession-resistant, such as healthcare, infrastructure, and non-discretionary consumer goods. An example would be BioSyent $RX.V, which sells critical healthcare products in the Canadian market. ✅ Technology companies. Software-as-a-Service (SaaS) companies seem reasonably insulated from the global trade war, whether they sell in the US, Canada, or abroad. I've always had a high technology allocation in my portfolio, and this is an area that I haven't changed much lately. I tend to prefer B2B software companies that are mission-critical to their customers because they should keep high customer retention rates even through downturns. A good example of a company I’m watching is Kneat $KSI.TO. ✅ Cash. Although I'm not a big fan of timing the market, there are times when being more defensive is appropriate. I like Howard Marks' approach in that regard. His thought experiment is to travel into the future, look back at today, and ask himself if he wished he'd been more aggressive or defensive back then. "What you think you might say a few years down the road can help you figure out what you should do today." When I perform this exercise and think about all the global uncertainty, on top of elevated large-cap valuations, I feel like I should err on the side of caution. Defensive can mean holding a bit more cash than usual. It can also mean holding stocks with stronger downside protection and shedding some of the more speculative assets (i.e. unprofitable high-growth companies, cryptocurrency-related companies, story stocks, etc.) In a perfect world, we could all rebalance our portfolios right away without any market impact and at the valuations we want. Unfortunately, the reality is far more nuanced. There are transaction costs, tax implications, and liquidity issues. The market could rebound next week and go on to make new highs, or it could go down another 30%. Trump might implement long-term tariffs and significantly hurt the Canadian economy for years to come, or he could back off and revert to a friendly stance. In times of uncertainty, it's crucial to think in probabilities. How will my portfolio fare if X happens? What if Y happens? What about Z? Suppose you assign probabilities to different scenarios and weigh your portfolio positions based on the probable outcomes. Hopefully, you'll win most of the time and won't lose too much the rest of the time. That’s why we own portfolios of stocks with different risk and reward profiles instead of a single stock. We have to make educated guesses and surrender the outcome. Just like a good poker player! Thank you for reading 🙏 Let me know your thoughts in the comments! And if you like this content, consider subscribing to my FREE weekly newsletter here: linktr.ee/stocksandstones

Nextplat Amplitech Crown electrokinetics Innovation beverage group Golden matrix group Senestech Microbix biosystem

Microbix Expanding Addressable Market Share with Test Makers

If you’re a serious investor and can wait 3 years for a potential 10x return, check out Microbix Biosystems Inc. $MBX.TO: Breakeven at $5M/quarter. After that: 50% profit on each additional dollar. Often overlooked as a “lumpy revenue” company.

Microbix Biosystems 2024 Annual FINS Review: $MBX.TO #FinsDontLie